NFKB1 and lip and oral cavity carcinoma: Here we suggest that therapeutic effect of sorafenib combined with radiation against human oral carcinoma could be through the inhibition of RANKL/p-ERK/NF-κB pathway and the reduction of NF-κB regulated downstream effector proteins (Fig. 5).